Does tighter perioperative glycemic control improve outcomes for diabetic patients undergoing coronary artery bypass graft surgery?

Cheng, Alice Y. Y.
July 2004
CMAJ: Canadian Medical Association Journal;7/6/2004, Vol. 171 Issue 1, p30
Academic Journal
Presents a clinical trial examining the effect of tighter glycemic control on diabetic patients undergoing coronary bypass graft surgery. Design of the control trial; Effect of glucose-insulin-potassium (GIK) infusion on postoperative outcome; Mechanisms through which benefits from GIK infusion may occur.


Related Articles

  • Short-Acting Insulin Analogues vs. Human Insulin for Diabetes. Schooff, Michael; Ehlers, Krista // American Family Physician;9/1/2005, Vol. 72 Issue 5, p805 

    Background. In short-acting insulin analogues the dissociation of hexamers is facilitated, achieving peak plasma concentrations about twice as high and within approximately one half the time compared with regular human insulin. According to these properties, this profile resembles the shape of...

  • Commentary. Murphy, Matthew; Dinneen, Sean // Evidence Based Medicine;Jun2006, Vol. 11 Issue 3, p77 

    The article comments on the medical research entitled "Inhaled Insulin Added Onto or Replacing Two Oral Agents Reduced Hemoglobin A1c concentrations in type 2 diabetes. The author cited that the design of the study, using comparator group without treatment intensification, overestimates inhaled...

  • Are You Waiting to Inhale? Weiger, Pamela; Whitfield, William; Farnsworth, Steve; Miller, Jacqueline; Moyer, Tina; Menninger Jr., Florian // Diabetes Health;Apr2006, Vol. 15 Issue 4, p41 

    Relates the opinions of diabetics in the U.S. on the market launching of Exubera, the noninjectible insulin from Pfizer Inc. Doubts concerning the drug; Consultation with an endocrinologist; Experience of a patient during a clinical trial on the drug.

  • (How) Can We Prevent Type 2 Diabetes? Buchanan, Thomas A. // Diabetes;Jun2007, Vol. 56 Issue 6, p1502 

    The article offers ways to prevent type 2 diabetes and present the pathogenesis of the disease. Randomized controlled trials were conducted to test the impact of behavioral and pharmacological interventions on rates of development of this disease on high-risk groups. In this type of diabetes,...

  • Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections. Retnakaran, Ravi; Hochman, Jackie; DeVries, J. Hans; Hanaire-Broutin, Helene; Heine, Robert J.; Melki, Vincent; Zinman, Bernard // Diabetes Care;Nov2004, Vol. 27 Issue 11, p2590 

    OBJECTIVE -- Rapid-acting insulin analogs (insulin lispro and insulin aspart) have emerged as the meal insulin of choice in both multiple daily insulin injection (MDII) therapy and continuous subcutaneous insulin infusion (CSII) for type 1 diabetes. Thus, a comparison of efficacy between CSII...

  • Mechanisms of Early Insulin-Sensitizing Effects of Thiazolidinediones in Type 2 Diabetes. Tonelli, Julia; Li, Weijie; Kishore, Preeti; Pajvani, Utpal B.; Kwon, Elize; Weaver, Charles; Scherer, Philipp E.; Hawkins, Meredith // Diabetes;Jun2004, Vol. 53 Issue 6, p1621 

    Whereas thiazolidinediones (TZDs) are known to rapidly improve insulin action in animals, short durations of TZD therapy have never been studied in humans. Among the many known actions of TZDs, increased circulating levels of the high molecular weight (HMW) multimer of adiponectin may be an...

  • Type 2 diabetes: The role of basal insulin therapy. LeRoith, Derek; Levatan, Claresa S.; Hirsch, Irl B.; Riddle, Matthew C. // Journal of Family Practice;Mar2004, Vol. 53 Issue 3, p215 

    The efficiency and efficacy of adding basal insulin to existing oral antidiabetic agents, used against type-2 diabetes, was demonstrated in the randomized, open-label Treat-to-Target Trial. New evidence and methods continue to alter management of patients with type-2 diabetes. Appropriate...

  • Early Aggressive Therapy in Type 2 Diabetes Pays Off.  // Clinical Cardiology Alert;Aug2008 Primary Care Supplement, Vol. 13 Issue 8, p15 

    The article discusses research on early treatment against type 2 diabetes (DM2). It references a study by J. Weng et al published in a 2008 issue of the "Lancet." The clinical trial which involved patients with DM2 focused on the effectiveness of intensive insulin regimens (IIR) and oral...

  • Trials That Matter: Rosiglitazone, Ramipril, and the Prevention of Type 2 Diabetes. Nathan, David M. // Annals of Internal Medicine;3/20/2007, Vol. 146 Issue 6, p461 

    The article focuses on the development of the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication trial. This trial is designed to identify if ramipril and rosiglitazone could prevent type 2 diabetes. Both drugs are generally safe and had a low frequency of severe adverse...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics